Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 19/20 | 0.67 |
| ▸ | PPARG | P37231 | 16/20 | 0.67 |
| ▸ | PPARD | Q03181 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5416979 | 1.00 | PPARA (0.67) | PPARAPPARGPPARD | |
| SCHEMBL5416971 | 1.00 | PPARA (0.67) | PPARAPPARGPPARD | |
| SCHEMBL5726635 | 0.93 | PPARA (0.63) | PPARAPPARGPPARD | |
| SCHEMBL5726640 | 0.93 | PPARA (0.63) | PPARAPPARGPPARD | |
| SCHEMBL5427010 | 0.93 | PPARG (0.66) | PPARAPPARGPPARD | |
| SCHEMBL5427011 | 0.93 | PPARG (0.66) | PPARAPPARGPPARD | |
| SCHEMBL5429733 | 0.92 | PPARA (0.67) | PPARAPPARGPPARD | |
| SCHEMBL5427997 | 0.92 | PPARA (0.67) | PPARAPPARGPPARD | |
| SCHEMBL5421831 | 0.92 | PPARA (0.67) | PPARAPPARGPPARD | |
| SCHEMBL5726947 | 0.90 | PPARG (0.73) | PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1502590-B1 | Heterocyclic oxime derivatives, process for their preparation and use thereof in the treatment of type II diabetes | SERVIER LAB (FR) | 2006-12-20 | — | — | EP | claimed |
| EP-1502590-A1 | Heterocyclic oxime derivatives, process for their preparation and use thereof in the treatment of type II diabetes | Les Laboratoires Servier (FR) | 2005-02-02 | — | — | EP | claimed |
| US-20070167502-A1 | Association between a heterocyclic compound and an antioxidant agent | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2007-07-19 | — | — | US | disclosed |
| EP-1502590-B1 | Heterocyclic oxime derivatives, process for their preparation and use thereof in the treatment of type II diabetes | SERVIER LAB (FR) | 2006-12-20 | — | — | EP | disclosed |
| EP-1729767-A1 | COMBINATION OF A HETEROCYCLIC COMPOUND AND AN ANTIOXIDANT AND USE THEREOF FOR TREATING OBESITY | Les Laboratoires Servier (FR) | 2006-12-13 | — | — | EP | disclosed |
| US-7071221-B2 | Heterocyclic oxime compounds | LES LABORATOIRES SERVIER (FR) | 2006-07-04 | — | — | US | disclosed |
| WO-2005099694-A1 | COMBINATION OF A HETEROCYCLIC COMPOUND AND AN ANTIOXIDANT AND USE THEREOF FOR TREATING OBESITY | LES LABORATOIRES SERVIER (FR) | 2005-10-27 | — | — | WO | disclosed |
| US-20050026973-A1 | New heterocyclic oxime compounds | LES LABORATOIRES SERVIER (FR) | 2005-02-03 | — | — | US | disclosed |
| EP-1502590-A1 | Heterocyclic oxime derivatives, process for their preparation and use thereof in the treatment of type II diabetes | Les Laboratoires Servier (FR) | 2005-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167502-A1 | Association between a heterocyclic compound and an antioxidant agent | PC, LIPC, GPR119 | PPARA 89/4885PPARG 47/4885PPARD 334/4885 |
| US-20050026973-A1 | New heterocyclic oxime compounds | CBR3, CBR1, CYB5R3 | PPARA 1112/4885PPARG 785/4885PPARD 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.